Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP14 | P54578 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.34 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2181398 | 0.93 | HSP90AA1 (0.41) | USP14HSP90AA1 | |
| SCHEMBL2182539 | 0.91 | USP14 (0.33) | USP14HSP90AA1PARP14TNF | |
| SCHEMBL2182535 | 0.89 | USP14 (0.35) | USP14PARP14KCNA5MAPKAPK2 | |
| SCHEMBL2184534 | 0.88 | HSP90AA1 (0.37) | USP14HSP90AA1PARP14KCNA5MAPKAPK2 | |
| SCHEMBL2183331 | 0.83 | USP14 (0.34) | USP14HSP90AA1PARP14KCNA5 | |
| SCHEMBL2183419 | 0.82 | HSP90AA1 (0.36) | USP14HSP90AA1PARP14KCNA5 | |
| SCHEMBL2180311 | 0.82 | HSP90AA1 (0.37) | USP14HSP90AA1 | |
| SCHEMBL13658409 | 0.82 | HSP90AA1 (0.43) | HSP90AA1 | |
| SCHEMBL2183498 | 0.81 | HSP90AA1 (0.44) | HSP90AA1 | |
| SCHEMBL3415025 | 0.81 | AXL (0.41) | USP14PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309721-B2 | HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof | SANOFI (FR) | 2012-11-13 | — | — | US | disclosed |
| US-20110166169-A1 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-07 | — | — | US | disclosed |
| EP-2265598-A2 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | Sanofi-Aventis (FR) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009122034-A2 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166169-A1 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | HSP90AB2P, HSP90AB1, HSP90AA1 | USP14 2783/4885HSP90AA1 3/4885PARP14 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.